Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

March 25, 2024

https://www.globenewswire.com/news-release/2024/03/25/2851497/0/en/Sagimet-Biosciences-Announces-Appointment-of-Tim-Walbert-and-Paul-Hoelscher-to-its-Board-of-Directors.html

SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Sagimet, Nasdaq:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.